Explore
Validate
LearnAMAb91123
antibody from Atlas Antibodies
Targeting: LAMA3
BM600-150kDa, epiligrin, kalinin-165kDa, LAMNA, nicein-150kDa
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AMAb91123 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#AMAb91123, RRID:AB_2665808
- Product name
- Anti-LAMA3
- Antibody type
- Monoclonal
- Description
- Monoclonal Antibody against Human LAMA3, Clone ID: CL3112, Gene description: laminin, alpha 3, Alternative Gene Names: BM600-150kDa, epiligrin, kalinin-165kDa, LAMNA, nicein-150kDa, Validated applications: IHC, WB, Uniprot ID: Q16787, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- CL3112
- Vial size
- 100 µl
- Concentration
- 0.5 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Photoreceptor laminin drives differentiation of human pluripotent stem cells to photoreceptor progenitors that partially restore retina function
Laminin N-terminus α31 protein distribution in adult human tissues
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Tay H, Andre H, Chrysostomou V, Adusumalli S, Guo J, Ren X, Tan W, Tor J, Moreno-Moral A, Plastino F, Bartuma H, Cai Z, Tun S, Barathi V, Siew Wei G, Grenci G, Chong L, Holmgren A, Kvanta A, Crowston J, Petretto E, Tryggvason K
Molecular Therapy 2023;31(3):825-846
Molecular Therapy 2023;31(3):825-846
Laminin N-terminus α31 protein distribution in adult human tissues
Stanton J, Troughton L, Reuten R, Sugden C, Hamill K
PLOS ONE 2020;15(12):e0239889
PLOS ONE 2020;15(12):e0239889
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Jun 15;23(12):3168-3180
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Jun 15;23(12):3168-3180
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human stomach and lymph node tissues using AMAb91123 antibody. Corresponding LAMA3 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
